FDA Panel Votes in Favor of Effectiveness of Forest Labs’ Daxas – Dow Jones reports that US FDA Panel has voted 9-6 in favor of Forest Labs (FRX), Nycomed drug Daxas which has shown effectiveness for COPD maintenance.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply